Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YUKAWA-2: Evolocumab in Japanese Subjects with Hyperlipidemia
NCT01953328Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2013
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, mixed dyslipidemia, sponsored by Amgen. Started Oct 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01953328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953328.